Visualizing the Mechanism of Bispecific Antibodies in NHL: Understanding Efficacy, Safety, and Applications in Refractory Disease

FACULTY

Jeremy S. Abramson, MD, MMSc
Associate Professor of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, MA

PROGRAM OVERVIEW

Through this virtual preceptorship program, learners will evaluate current and emerging applications of bispecific antibodies in the management of non-Hodgkin lymphoma, as informed by the latest data. With multiple novel bispecific antibodies targeting CD20 on malignant B cells and CD3 on immune effector T cells, there is an increasing need for awareness of the efficacy, safety, and best practices for use of these therapies in relapsed and refractory forms of non-Hodgkin lymphomas. In addition to recognizing clinical data and mechanisms, this program discusses potential adverse events associated with bispecific antibody therapies and best practices for their monitoring and management. This unique program enables clinicians to understand the design, mechanisms, and safety and efficacy data informing the integration of bispecific antibodies in management of non-Hodgkin lymphomas.

TARGET AUDIENCE

This activity is designed to meet the educational needs of medical oncologists, hematologists, nurse practitioners, pharmacists, and other members of the multidisciplinary oncology care team.

LEARNING OBJECTIVES

  • Assess the latest approaches to use of novel bispecific antibody therapies for NHL
  • Summarize current clinical data in NHL management in consideration of outcomes with bispecific antibody therapies
  • Evaluate adverse event data associated with bispecific antibodies to inform appropriate management of potential adverse events in patients within NHL

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.

PHYSICIAN CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of .75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Med Learning Group. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


NURSES (ANCC) CREDIT DESIGNATION

Amedco LLC designates this activity for a maximum of .75 ANCC contact hour.

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS

Faculty Relationship Manufacturer
Jeremy S. Abramson, MD Consultant AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Caribou Biosciences, Cellectar Biosciences, Century Therapeutics, Epizyme, Genentech, Genmab, Incyte, Interius, Janssen, Kite Pharma, Lilly, and Takeda.

All relevant financial relationships have been mitigated.

CME Content Review

The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review

The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff Planners and Managers

The staff, planners, and managers reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this activity:

  • Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
  • Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
  • Michael Page, PharmD, RPh, Medical Director for Med Learning Group, has nothing to disclose.
  • Lauren Welch, MA, VP, Outcomes and Accreditation for Med Learning Group has nothing to disclose.
  • Daniel DaSilva, Outcomes and Accreditation Coordinator for Med Learning Group has nothing to disclose.
  • Felecia Beachum, Sr. Program Manager for Med Learning Group has nothing to disclose.
  • Naomi De Brito, Associate Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at https://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

RELEASED DATE: January 26, 2024
EXPIRATION DATE: January 26, 2025

Copyright ©2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Pin It on Pinterest

Directory
Scroll to Top